title: Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
abstract: OBJECTIVE
  To determine if pegaptanib (Macugen) [Eyetech Pharmaceuticals; Pfizer Inc, New York, New York, USA] injections cause adverse intraocular pressure (IOP) effects in patients with and without glaucoma.
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  Review of 75 eyes treated with intravitreal injections of pegaptanib (0.09 ml). The effect of these injections on IOP was analyzed. Most patients received prophylactic IOP-lowering medications.
  
  
  RESULTS
  The mean preinjection IOP based on the first injection of each patient was 14 +/- 3 mm Hg; at one minute postinjection, 38 +/- 14 mm Hg, at three to 10 minutes was 34 +/- 9 mm Hg, and at 11 to 20 minutes was 26 +/-10 mm Hg, respectively. Most patients' IOPs had significantly diminished by 30 minutes postinjection.
  
  
  CONCLUSIONS
  Pegaptanib injections result in a significant transient rise in IOP that considerably diminishes by 30 minutes postinjection but can take up to one hour. This may be damaging to the optic nerve, particularly in patients with advanced glaucoma.
authors.affiliation: Eye Research Foundation, Stuart, Florida, USA. efleye@aol.com
authors.forename: Ronald E P
authors.initials: RE
authors.lastname: Frenkel
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Mani
authors.forename: Allison R
authors.initials: AR
authors.lastname: Toler
authors.forename: Max P C
authors.initials: MP
authors.lastname: Frenkel
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D005902:Glaucoma, Open-Angle / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D012189:Retrospective Studies; D013997:Time Factors; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D000959:Antihypertensive Agents; D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib